Table D42. Adverse event outcomes 1

| Author, Year  Trial Name | Adverse Events 1 | Description of Timing of Measurement of Outcome | Data Source | N | Results | Did the intervention(s) result in worsened health or other outcomes? If so, list worsened outcomes here |
| --- | --- | --- | --- | --- | --- | --- |
| Carter et al., 200910 NA | Mean total adverse effect score | Measured twice, once at baseline & once at 6 month follow-up | Adverse event questionnaire with 47 items, developed for another study & personally administered by study nurses | G1: 192 G2: 210 | **BL** (Mean (SD))  G1: 28.0 (23.0)  G2: 42.1 (24.2) 95% CI, NR p: <0.001  **6 month follow-up** (Mean (SD))  G1: 16.6 (12.5)  G2: 39.2 (24.2) 95% CI, NR p: <0.001  Between group difference at 6 months p < 0.001. However, this does not adjust for difference at baseline. | No |
| Murray et al., 200736 NA | Number of patients who had an adverse drug event or medication error | NR | Measured using a program that identified adverse events from the medical record system | G1: 112 (unclear why different from 122 for every other outcome) G2: 192 | G1: 42 (37.5%) G2: 91 (47.4%) 95% CI, NR p: Chi-sq 0.094; between-group rate comparison 0.108 | No |
| Schectman et al., 199448  NA | Proportion of patients reporting of adverse events associated with medications at 2 months | 2 months; measured at 2, 4, and 6 months though only 2 month results reported | Self-report to clinic staff | Niacin: G1: 40 G2: 40  BAS:  G1: 18 G2: 20 | Niacin: flushing, pruritus, rash, heartburn (%) G1: 70, 32, 15, 9 G2: 63, 29, 12, 5 95% CI, NR p: NS, no number given  BAS: constipation, bloating, flatulence, heartburn (%) G1: 44, 23, 19, 15 G2: 26, 22, 11, 11 95% CI, NR p: NS, no number given | No |
| Weymiller et al., 200762 Statin Choice Randomized Trial  Jones et al., 200963 Statin Choice Randomized Trial | Termination of statin use due to associated adverse events | NR | Clinician assessment | G1: 52 G2: 46 | G1: 0 G2: 2 95% CI, NR p: NR | No |